DEBRA research invests in Topadur to advance small-molecule therapies for dystrophic Epidermolysis bullosa
DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage